397 related articles for article (PubMed ID: 17319852)
1. Intratumoral heterogeneity of HER2/neu in breast cancer--a rare event.
Hanna W; Nofech-Mozes S; Kahn HJ
Breast J; 2007; 13(2):122-9. PubMed ID: 17319852
[TBL] [Abstract][Full Text] [Related]
2. The role of HER2/neu overexpression/amplification in the progression of ductal carcinoma in situ to invasive carcinoma of the breast.
Latta EK; Tjan S; Parkes RK; O'Malley FP
Mod Pathol; 2002 Dec; 15(12):1318-25. PubMed ID: 12481013
[TBL] [Abstract][Full Text] [Related]
3. Genotypic intratumoral heterogeneity in breast carcinoma with HER2/neu amplification: evaluation according to ASCO/CAP criteria.
Brunelli M; Manfrin E; Martignoni G; Miller K; Remo A; Reghellin D; Bersani S; Gobbo S; Eccher A; Chilosi M; Bonetti F
Am J Clin Pathol; 2009 May; 131(5):678-82. PubMed ID: 19369627
[TBL] [Abstract][Full Text] [Related]
4. HER2/neu expression and gene alterations in pancreatic ductal adenocarcinoma: a comparative immunohistochemistry and chromogenic in situ hybridization study based on tissue microarrays and computerized image analysis.
Tsiambas E; Karameris A; Dervenis C; Lazaris AC; Giannakou N; Gerontopoulos K; Patsouris E
JOP; 2006 May; 7(3):283-94. PubMed ID: 16685109
[TBL] [Abstract][Full Text] [Related]
5. Intratumoral heterogeneity of her-2/neu in invasive mammary carcinomas using fluorescence in-situ hybridization and tissue microarray.
Shin SJ; Hyjek E; Early E; Knowles DM
Int J Surg Pathol; 2006 Oct; 14(4):279-84. PubMed ID: 17041191
[TBL] [Abstract][Full Text] [Related]
6. Amplification of Her-2/neu gene in Her-2/neu-overexpressing and -nonexpressing breast carcinomas and their synchronous benign, premalignant, and metastatic lesions detected by FISH in archival material.
Xu R; Perle MA; Inghirami G; Chan W; Delgado Y; Feiner H
Mod Pathol; 2002 Feb; 15(2):116-24. PubMed ID: 11850540
[TBL] [Abstract][Full Text] [Related]
7. Comparing fluorescence in situ hybridization and chromogenic in situ hybridization methods to determine the HER2/neu status in primary breast carcinoma using tissue microarray.
Park K; Kim J; Lim S; Han S; Lee JY
Mod Pathol; 2003 Sep; 16(9):937-43. PubMed ID: 13679458
[TBL] [Abstract][Full Text] [Related]
8. HER2 status in pure ductal carcinoma in situ and in the intraductal and invasive components of invasive ductal carcinoma determined by fluorescence in situ hybridization and immunohistochemistry.
Park K; Han S; Kim HJ; Kim J; Shin E
Histopathology; 2006 May; 48(6):702-7. PubMed ID: 16681686
[TBL] [Abstract][Full Text] [Related]
9. The expression of the cytoskeletal focal adhesion protein paxillin in breast cancer correlates with HER2 overexpression and may help predict response to chemotherapy: a retrospective immunohistochemical study.
Short SM; Yoder BJ; Tarr SM; Prescott NL; Laniauskas S; Coleman KA; Downs-Kelly E; Pettay JD; Choueiri TK; Crowe JP; Tubbs RR; Budd TG; Hicks DG
Breast J; 2007; 13(2):130-9. PubMed ID: 17319853
[TBL] [Abstract][Full Text] [Related]
10. Analysis of the HER2/neu gene amplification in microdissected breast cancer tumour samples.
Seth RM; Burger AM; Kahn HJ
Anticancer Res; 2006; 26(2A):927-31. PubMed ID: 16619488
[TBL] [Abstract][Full Text] [Related]
11. Histological tumor grade correlates with HER2/c-erB-2 status in invasive breast cancer: a comparative analysis between immunohistochemical (CB11 clone and Herceptest), FISH and differential PCR procedures.
López-Guerrero JA; Navarro S; Noguera R; Almenar S; Pellin A; Vázquez C; Llombart-Bosch A
Arkh Patol; 2003; 65(1):50-5. PubMed ID: 12669615
[TBL] [Abstract][Full Text] [Related]
12. Real-time RT-PCR analysis for evaluating the Her2/neu status in breast cancer.
Cuadros M; Talavera P; López FJ; García-Peréz I; Blanco A; Concha A
Pathobiology; 2010; 77(1):38-45. PubMed ID: 20185966
[TBL] [Abstract][Full Text] [Related]
13. HER2/neu amplification in breast cancer: stratification by tumor type and grade.
Hoff ER; Tubbs RR; Myles JL; Procop GW
Am J Clin Pathol; 2002 Jun; 117(6):916-21. PubMed ID: 12047143
[TBL] [Abstract][Full Text] [Related]
14. Cyclooxygenase-2 expression in human breast cancers and adjacent ductal carcinoma in situ.
Half E; Tang XM; Gwyn K; Sahin A; Wathen K; Sinicrope FA
Cancer Res; 2002 Mar; 62(6):1676-81. PubMed ID: 11912139
[TBL] [Abstract][Full Text] [Related]
15. [Expression of Her2/neu in locally advanced bladder cancer: implication for a molecular targeted therapy].
Wülfing C; von Struensee D; Bierer S; Bögemann M; Hertle L; Eltze E
Aktuelle Urol; 2005 Sep; 36(5):423-9. PubMed ID: 16163605
[TBL] [Abstract][Full Text] [Related]
16. Histopathologic characteristics predicting HER-2/neu amplification in breast cancer.
Prati R; Apple SK; He J; Gornbein JA; Chang HR
Breast J; 2005; 11(6):433-9. PubMed ID: 16297088
[TBL] [Abstract][Full Text] [Related]
17. The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy.
Ross JS; Fletcher JA
Stem Cells; 1998; 16(6):413-28. PubMed ID: 9831867
[TBL] [Abstract][Full Text] [Related]
18. Correlations among p53, Her-2/neu, and ras overexpression and aneuploidy by multiparameter flow cytometry in human breast cancer: evidence for a common phenotypic evolutionary pattern in infiltrating ductal carcinomas.
Smith CA; Pollice AA; Gu LP; Brown KA; Singh SG; Janocko LE; Johnson R; Julian T; Hyams D; Wolmark N; Sweeney L; Silverman JF; Shackney SE
Clin Cancer Res; 2000 Jan; 6(1):112-26. PubMed ID: 10656439
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of HER2 gene amplification in invasive breast cancer using a dual-color chromogenic in situ hybridization (dual CISH).
Kato N; Itoh H; Serizawa A; Hatanaka Y; Umemura S; Osamura RY
Pathol Int; 2010 Jul; 60(7):510-5. PubMed ID: 20594272
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of HER2/neu gene amplification in patients with invasive breast carcinoma. Comparison of in situ hybridization methods.
Sińczak-Kuta A; Tomaszewska R; Rudnicka-Sosin L; Okoń K; Stachura J
Pol J Pathol; 2007; 58(1):41-50. PubMed ID: 17585541
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
